The U.S. Food and Drug Administration (FDA) is taking steps to make lower-cost alternatives to expensive biologic medicines more accessible. New regulatory guidance announced in October 2025 aims to simplify the approval process for biosimilar drugs, potentially reducing development costs, encouraging competition, and expanding treatment options for patients.
The move could mark an important shift in how these medications reach the market, particularly for people managing chronic conditions or serious illnesses that require long-term treatment.
A New Approach to Biosimilar Approval
Biosimilars are medications developed to closely resemble existing biologic drugs. Unlike traditional medicines, which are generally made using chemical processes, biologics are produced using living cells and are often used to treat complex conditions such as cancer, diabetes, and autoimmune disorders.
Although biosimilars serve a similar purpose to generic drugs, their development is considerably more complicated. Manufacturers must demonstrate that their products are highly similar to an already approved biologic and that there are no clinically meaningful differences in safety or effectiveness.
Under the FDA's updated guidance, certain biosimilar developers may no longer need to conduct extensive comparative clinical studies in humans when other scientific evidence is sufficient to establish similarity.
Instead, manufacturers can rely more heavily on analytical data, including detailed assessments of molecular structure, biological activity, and manufacturing consistency.
This approach is intended to eliminate unnecessary duplication in the approval process while maintaining the scientific standards required for patient safety.
According to reporting by The New York Times, the changes could significantly shorten development timelines, potentially reducing a process that previously took five to eight years to just a few years in some cases.
FDA Commissioner Dr. Marty Makary has said the updated approach is designed to reduce development expenses without compromising the safety or effectiveness of approved treatments. Lower development costs could also create opportunities for more affordable medications to enter the market.
Making Biosimilars Easier to Access
The regulatory changes are not limited to drug development. The FDA also intends to simplify aspects of biosimilar substitution, potentially making it easier for pharmacists to provide eligible alternatives to brand-name biologic medications.
Interchangeable biosimilars can be substituted for their reference products under applicable state pharmacy laws, often without requiring a separate prescription change from the prescribing healthcare professional.
Making these alternatives easier to identify and access could encourage broader adoption, increase competition, and give patients and healthcare providers more flexibility when choosing treatments.
However, substitution rules and pharmacy practices still vary by state, and not every biosimilar automatically qualifies for interchangeable status.
Industry Leaders Question Where the Real Barriers Remain
The FDA's announcement has attracted attention across the pharmaceutical industry, where the cost and complexity of bringing biosimilars to market have long been subjects of debate.
U.S. Health Secretary Robert F. Kennedy Jr. argued that regulatory obstacles have historically limited competition and helped established pharmaceutical companies maintain their market positions.
However, some industry analysts believe that changing FDA requirements alone may not be enough to transform the biosimilar market.
Brian Skorney, a pharmaceutical industry analyst at investment bank Baird, pointed to patent protections and litigation involving brand-name drug manufacturers as major obstacles that can delay the arrival of competing products.
His assessment highlights an important distinction: even when a biosimilar receives regulatory approval, legal disputes and commercial arrangements may still influence when it becomes available to patients.
The pharmaceutical industry's main lobbying organization, the Pharmaceutical Research and Manufacturers of America (PhRMA), also raised concerns about the role of pharmacy benefit managers (PBMs). These organizations negotiate prescription drug benefits and influence how medications are covered and reimbursed.
The debate reflects the complexity of prescription drug pricing, where regulatory requirements, patent protections, insurance arrangements, and commercial incentives can all affect access to lower-cost treatments.
How Far Has the Biosimilar Market Come?
The United States approved its first biosimilar in 2015. Since then, more than 60 biosimilar products have entered the U.S. market, creating alternatives to several widely prescribed biologic medications.
Some notable examples include:
- Herceptin: A biologic treatment used for certain types of breast and other cancers.
- Lantus: A long-acting insulin used to manage diabetes.
- Humira: A medication prescribed for several inflammatory and autoimmune conditions.
Despite this progress, biosimilars still represent a relatively small share of total prescription drug spending compared with their potential to reduce healthcare costs.
Generic and biosimilar medications account for approximately 90% of U.S. prescriptions, according to figures cited by The New York Times. However, their share of overall prescription spending is considerably smaller.
This difference reflects the substantial cost of many biologic medicines and the financial pressure they can place on patients, healthcare providers, and insurance systems.
What the Changes Could Mean for Patients
The FDA's updated approach is intended to encourage more manufacturers to invest in biosimilar development by reducing unnecessary regulatory expenses and shortening approval timelines.
If successful, the changes could contribute to:
- More competition: Additional biosimilar manufacturers could enter the market, creating alternatives to established biologic drugs.
- Lower development costs: Simplified approval requirements could reduce the financial burden associated with bringing new products to market.
- Broader treatment access: Greater availability of biosimilars could give patients and healthcare providers more options.
- Potential cost savings: Increased competition may put downward pressure on medication prices over time.
However, regulatory changes do not guarantee immediate price reductions. Actual savings will depend on market competition, patent disputes, insurance coverage, pharmacy benefit arrangements, and how quickly new products become commercially available.
The Road Ahead for More Affordable Medicines
The FDA's effort to modernize biosimilar regulations represents a significant development in the ongoing discussion about prescription drug affordability.
By placing greater emphasis on scientific evidence and reducing unnecessary duplication in clinical testing, regulators hope to make biosimilar development more efficient without lowering safety standards.
Still, the long-term impact will depend on more than approval timelines. Patent-related challenges, industry competition, reimbursement policies, and access through pharmacies will all influence how much patients ultimately benefit.
For people who rely on expensive biologic treatments, the potential expansion of lower-cost alternatives offers a reason for cautious optimism. If the reforms achieve their intended goals, biosimilars could become a more accessible part of the U.S. healthcare system, giving patients additional treatment choices and helping address some of the financial challenges associated with modern medicine.